A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients1,2

2003 ◽  
Vol 75 (8) ◽  
pp. 1404-1408 ◽  
Author(s):  
Keshwar Baboolal
Sign in / Sign up

Export Citation Format

Share Document